Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 12/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9903377 | 0.84 | GRM5 (0.73) | GRM5TNIK | |
| SCHEMBL9903825 | 0.84 | GRM5 (0.72) | GRM5 | |
| SCHEMBL18946207 | 0.79 | GRM5 (0.65) | GRM5TNIK | |
| SCHEMBL24463055 | 0.76 | GRM5 (0.61) | GRM5CHRNB2CHRNA4CHRNB1CHRNB4 | |
| SCHEMBL2051024 | 0.73 | GRM5 (0.65) | GRM5GRM4 | |
| SCHEMBL678784 | 0.71 | GRM5 (0.55) | GRM5GRM4 | |
| SCHEMBL2767773 | 0.69 | GRM5 (0.52) | GRM5GRM4 | |
| SCHEMBL9902642 | 0.68 | GRM5 (0.51) | GRM5PDGFRBPDGFRAGRM4APP | |
| SCHEMBL9902619 | 0.68 | GRM5 (0.51) | GRM5PDGFRBPDGFRAAPP | |
| SCHEMBL10238681 | 0.67 | GRM5 (0.50) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | claimed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | claimed |
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-07-12 | — | — | US | disclosed |
| EP-2462142-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | Merz Pharma GmbH & Co. KGaA (DE) | 2012-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178742-A1 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS | GRM5, GRIK5, GRM1 | GRM5 1/4885PDGFRB 2633/4885PDGFRA 2220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.